Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375160 | 1.00 | KDM4E (0.49) | KDM4EGLAMAPK1MAPTGAA | |
| SCHEMBL30128568 | 0.88 | ALDH1A1 (0.51) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL4193150 | 0.88 | ALDH1A1 (0.51) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL6201094 | 0.86 | MAPT (0.52) | KDM4EMAPK1MAPTGAAALDH1A1 | |
| SCHEMBL3870595 | 0.86 | KDM4E (0.59) | KDM4EMAPTGAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11509573 | 0.86 | ALDH1A1 (0.50) | KDM4EMAPTGAAALDH1A1HDAC3 | |
| Hydrochloric Acid SCHEMBL3871214 | 0.84 | KDM4E (0.57) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL6156472 | 0.84 | KDM4E (0.57) | KDM4EGLAMAPK1MAPTGAA | |
| SCHEMBL867417 | 0.82 | PRSS1 (0.47) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL215272 | 0.82 | HDAC3 (0.50) | KDM4EMAPTGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121931199-A | Method for synthesizing quinoxaline and derivative thereof by using chemical enzyme synergistic catalytic system | 南京工业大学 | 2026-04-28 | — | — | CN | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118530239-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115626927-B | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-3512488-B1 | HAIR COLOR COMPOSITIONS COMPRISING STABLE VIOLET-BLUE TO BLUE IMIDAZOLIUM DYES | WELLA OPERATIONS US LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115626927-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-4110772-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | KDM4E 3125/4885GLA 1658/4885MAPK1 1734/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | KDM4E 3125/4885GLA 1658/4885MAPK1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.